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Leptin, an adipocyte-secreted hormone, regulates energy homeostasis as well as reproductive, neuroendocrine, immune and 
metabolic functions. Subjects with decreased amounts of fat in their adipose tissue, i.e., lipoatrophy, have low leptin levels. In the 
context of open-label, uncontrolled studies leptin administration, in physiological replacement doses, has been shown to have 
metabolically salutary effects in the rare patients with the syndrome of congenital lipodystrophy accompanied by leptin deficien-
cy. Much more patients with lipodystrophy suffer from lipodystrophy and the metabolic syndrome associated with the use of 
highly active antiretroviral therapy. In this so called highly active antiretroviral therapy (HAART)-associated lipodystrophy and 
metabolic syndrome, patients demonstrate fat maldistribution with dyslipidemia, insulin resistance, and other metabolic com-
plications. Leptin administration has been shown to decrease central fat mass and to improve fasting insulin/glucose levels and 
insulin sensitivity in human immunodeficiency virus-infected hypoleptinemic patients with HAART induced lipodystrophy and 
the metabolic syndrome. By contrast, the results of leptin treatment in leptin replete or hyperleptinemic obese individuals with 
glucose intolerance and diabetes mellitus have been minimal or null, presumably due to leptin tolerance or resistance that impairs 
leptin action. In this review, we present the emerging clinical applications and potential therapeutic uses of leptin in humans with 
lipodystrophy and the metabolic syndrome.
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INTRODUCTION
Leptin plays a crucial role in the regulation of energy homeo-
stasis, insulin action and lipid metabolism [1]. As a hormone 
secreted by adipocytes in quantities which mainly reflect fat 
mass and secondarily acute energy deprivation as well as other 
factors, leptin serves as an important signal of body energy 
stores. Leptin deficiency in mice and/or in humans is associat-
ed with neuroendocrine and metabolic [1,2] abnormalities 
[3,4], including insulin resistance and diabetes. All these ab-
normalities are corrected by exogenous leptin administration 
[1,2,5,6], suggesting that leptin plays a role in glucose homeo-
stasis and possibly in the pathogenesis of other obesity-related 
metabolic complications. 
  Interestingly, leptin-induced normalization of hyperglyce-
mia and hyperinsulinemia in ob/ob mice is observed even be-
fore any alteration in body weight takes place, suggesting that 
leptin’s effects on glucose homeostasis are, in part, independent 
of its weight-reducing effects [5,6]. Similar to ob/ob mice, oth-
er mouse models of obesity and leptin resistance or tolerance 
[7-9] have abnormalities reminiscent of leptin deficiency due 
to subnormal leptin action [7,10,11]. The importance of leptin 
is also evident in human physiology [3,4,7-18]. Leptin admin-
istration has been demonstrated to successfully treat obesity 
and its complications in individuals with congenital leptin de-
ficiency, and thus leptin is available on a compassionate basis 
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for these patients [5-7]. 
  Recent evidence has suggested that leptin is effective in cor-
recting neuroendocrine abnormalities and insulin resistance 
in patients with human immunodeficiency virus (HIV)-asso-
ciated lipodystrophy [11-13,19] as well as congenital lipodys-
trophy [8-10]. 
CONGENITAL LIPODYSTROPHY
Lipodystrophy is a group of clinically heterogeneous acquired 
or inherited disorders characterized by complete or partial ab-
sence of subcutaneous fat that can occur in conjunction with 
the pathological accumulation of adipose tissue in other dis-
tinct regions of the body [10,20]. Though inherited lipodystro-
phies are exceedingly rare, acquired lipodystrophies (especial-
ly resulting HIV infection and its treatment) are more common. 
Interestingly, lipodystrophic patients exhibit insulin resistance, 
hyperglycemia, dyslipidemia, and hepatic steatosis [21]. The 
severity of these metabolic abnormalities typically correlates 
with the degree of adipose tissue loss (see below). 
  In humans, congenital lipodystrophy syndromes are rare; 
there have been less than a few hundred cases described in the 
literature and it is expected that there are less than 1,000 peo-
ple suffering from this condition in North America [22,23]. 
The lipodystrophies are associated with partial or total leptin 
deficiency [24]. Leptin replacement dramatically improved 
dyslipidemia and insulin sensitivity and reduced HbA1c levels 
and intrahepatic fat content in various types of human lipo-
dystrophy [25-32]. Fasting blood glucose and HbA1c levels 
decreased markedly even in patients who are not fully respon-
sive to other antihyperglycemic medications or high doses of 
insulin [28]. Hyperglycemic-euglycemic clamps in three pa-
tients with lipoatrophic diabetes have shown remarkable im-
provement in insulin sensitivity after leptin treatment [26]. 
This beneficial effect was seen with respect to both hepatic in-
sulin sensitivity and whole-body insulin sensitivity. In con-
junction with this, there was an 86% reduction in intrahepatic 
triglyceride content and a 33% reduction in muscle triglycer-
ide content [26]. In a recently published open-label, uncon-
trolled prospective study in 48 patients with various acquired 
and inherited forms of lipodystrophy [30], leptin replacement 
effectively decreased serum triacylglycerol concentrations by 
59% and HbA1c levels by 1.5 percentage-points within 1 year. 
The benefits of leptin replacement were sustained for up to 8 
years of follow-up in the context of open label studies [30]. Oral 
and Chan [32] collected several small, non-randomized, open-
label trials in a composite study reporting on a total of more 
than 100 patients with severe lipodystrophy. These studies have 
found improvement in several metabolic parameters, includ-
ing glycemic control, insulin sensitivity, plasma triglycerides, 
caloric intake, liver volume and lipid content, and intramyo-
cellular lipid content, with leptin treatment [33]. In summary, 
all these studies have demonstrated that leptin could be an ef-
fective regimen that can be used to overcome the metabolic 
abnormalities characteristic of lipodystrophy, and have pro-
vided the rationale for metreleptin treatment in these patients. 
However, there are several issues that deserve serious consid-
eration. Published reports are all open-label and uncontrolled; 
thus, a placebo-controlled trial is warranted to fully determine 
efficacy and safety. Given the small number of patients and the 
lack of firm diagnostic criteria are hurdles to perform a trial of 
parallel design, a cross over design should be more appropri-
ate in this case [23]. Future trials should also allow a compari-
son with the current standard of care. Importantly, the side ef-
fect profile of leptin has not yet been fully characterized; al-
though deterioration of renal function, lymphomas, and the 
development of antibodies to leptin have all been reported 
[32,34,35], it remains unknown whether these side effects are 
due to therapy versus the disease process per se. The optimal 
treatment regimen including dose and frequency has also not 
been determined. Nevertheless, metreleptin is available from 
the manufacturer for the treatment of leptin as part of the ex-
panded access program, and an application for approval for 
this indication is under review by the U.S. Food and Drug Ad-
ministration (FDA). 
HIGHLY ACTIVE ANTIRETROVIRAL 
THERAPY (HAART)-ASSOCIATED 
LIPODYSTROPHY 
More than 40 million people worldwide are currently living 
with HIV, including more than eight million individuals in 
Southeast Asia [36]. The widespread use of HAART has dra-
matically altered both the morbidity, mortality and long term 
outcomes but the prolonged life expectancy of patients receiv-
ing HAART, has also been associated with a dramatic increase 
of the incidence and prevalence of adverse effects and toxicity 
[37]. A frequently observed adverse effect of HAART involves 
metabolic abnormalities associated with lipodystrophy [38], 
i.e., the HAART-associated lipodystrophy syndrome (HALS).183
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HALS
Abnormal fat distribution, called the HALS, is associated with 
dyslipidemia, insulin resistance, and other metabolic compli-
cations [38,39]. The prevalence of these adverse effects de-
pends on the HAART regimen and increases with use over 
time [40,41]. Patients may experience lipoatrophy, lipohyper-
trophy, or clinical features of both [42]. Lipoatrophy occurs in 
approximately 20% of patients on HAART in our experience 
and is typically characterized by a loss of subcutaneous adi-
pose tissue in the face and extremities [37,41]. Other patients 
with HAART induced metabolic syndrome may have lipoat-
rophy in the extremeties in the context of stable or increased 
visceral adipose tissue and a normal or even increased waist:hip 
ratio [43]. At the other end of the spectrum, lipohypertrophy 
is characterized by generalized or central fat accumulation [44]. 
The majority of the patients on HAART display a combination 
of lipoatrophy and lipohypertrophy, called mixed lipodystro-
phy, which is also closely associated with metabolic abnormal-
ities [45]. 
  The pathogenesis of HAART associated lipodystrophy and 
the metabolic syndrome is thought to be multifactorial [40]. 
This process involves impairment of both adipocyte differenti-
ation and ectopic fat deposition either intra-abdominally or in 
areas other than the adipose tissue, such as liver, muscle, etc. 
[46]. This is associated with increased lipolysis [47], which in 
turn creates a lipotoxic environment with elevated serum free 
fatty acids (FFAs) and subsequent intracellular accumulation 
of FFAs. Ectopic deposition of FFAs in visceral adipose tissue, 
skeletal muscle, liver, and pancreas exacerbates dyslipidemia 
and insulin resistance [48] which eventually leads to metabolic 
syndrome and diabetes in susceptible individuals [49,50].
  Among HAART, protease inhibitors and nucleoside reverse 
transcriptase inhibitors (NRTIs) have been shown to affect in-
sulin resistance and glucose metabolism by seemingly differ-
ent pathways [51]. Protease inhibitors have been suggested to 
stimulate lipolysis while inhibiting adipocyte differentiation 
and lipogenesis by interfering with peroxisome proliferator-
activated receptor-gamma (PPAR-γ) [40]. NRTIs may cause li-
poatrophy secondary to mitochondrial injury within adipo-
cytes [40], and their toxic metabolic effects appear synergistic 
with protease inhibitors [52]. Non-nucleoside reverse transcrip-
tase inhibitors have also been implicated in this disease pro-
cess; however, the effects of this drug class are still being inves-
tigated [53]. Viral proteins and mechanisms related to HIV-1 
infection have also been suggested to influence adipose tissue 
distribution directly [54]. 
THE ROLE OF ADIPOKINES IN HALS
We and others have shown that levels of adipokines leptin and 
adiponectin are decreased in patients with HALS, suggesting 
that they may play a fundamental role in the metabolic abnor-
malities observed in lipodystrophy [44,55,56], replacement of 
adipokines could be a physiological approach to the therapy of 
the syndrome and may provide considerable therapeutic value 
for HALS patients. 
Adiponectin
Levels of the beneficial, adipocyte secreted hormone-insulin 
sensitizer adiponectin are low in obesity, diabetes, and subsets 
of individuals with lipodystrophy accompanied by central li-
pohypertrophy, including many patients with HALS [24,57-59]. 
Low adiponectin levels are associated with insulin resistance, 
hypertriglyceridemia, and adipose tissue redistribution in HIV 
patients receiving HAART [55]. Although adiponectin is not 
currently available for treatment in humans, studies in mice 
have demonstrated improved insulin sensitivity, dyslipidemia, 
and weight loss [17]. Further research is needed to determine 
the potential for adiponectin replacement, or the use of adipo-
nectin receptor analogues, in humans and the extent of its ef-
fects, specifically in HALS. In the meantime, we have shown 
that medications that increase adiponectin levels, such as pio-
glitazone, improve components of HALS (see below).
Leptin
Leptin is synthesized and secreted by adipocytes and is involved 
in energy homeostasis, while generally reflecting the amount 
of energy stores within the body [17]. Leptin acts centrally to 
promote satiety and decreased food intake [13], while also act-
ing peripherally to decrease gluconeogenesis in the liver and 
adipose tissue and increase glucose utilization by skeletal mus-
cle through pathways overlapping with insulin [60]. 
  A significant subgroup of patients with lipodystrophy ex-
hibit low leptin levels, including patients with HALS [44]. In 
studies in congenital and non-HIV related acquired lipodys-
trophy, physiological replacement doses of leptin (0.04 to 0.08 
mg/kg daily) have resulted in significant weight loss, improved 
insulin sensitivity and glucose tolerance, and reduced hemo-
globin A1c levels [25,26,28]. 184
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Similar results have been demonstrated in studies of patients 
with HALS. We have demonstrated that in a randomized, pla-
cebo-controlled, double-blinded crossover study in seven hy-
poleptinemic men with HALS, physiologic metreleptin replace-
ment doses administered for 2 months improved metabolic 
parameters in these patients. Leptin treatment was associated 
with a 14.6% adjusted decrease in central fat mass and signifi-
cant improvements in fasting glucose and insulin levels, insu-
lin resistance and high density lipoprotein cholesterol (HDL-
C) levels [61]. 
  A similar independent study of longer duration confirmed 
these results, demonstrating a 32% decrease in visceral fat, im-
proved lipid profiles, and increased hepatic insulin sensitivity 
with metreleptin treatment [62]. The improvements in central 
fat mass and lipid profiles observed in these studies [61,62] 
were comparable to those reported with metformin and thia-
zolidinediones in HALS patients [63-65], and provide an advan-
tage over growth hormone (GH) replacement because leptin has 
not been seen to cause glucose intolerance [66]. 
  Recombinant metreleptin therapy was well-tolerated in both 
studies, and their results suggest that the benefits of leptin re-
placement are sustained throughout treatment in patients with 
HALS [61,62]. Patients with various forms of congenital, non-
HIV related, lipodystrophy followed for up to 8 years have also 
demonstrated sustained benefit with uninterrupted metreleptin 
treatment [30]. 
FUTURE DIRECTIONS OF THERAPY
As each therapy discussed has shown some benefit to HALS 
patients, combination therapies are currently being studied for 
potential use in these patients. In a 3-month pilot study of 
leptin treatment in addition to pioglitazone in adult men with 
HALS, we observed improved insulin sensitivity and postpran-
dial glucose levels in comparison to pioglitazone treatment 
alone [67]. Improvements in body fat mass and distribution 
were not observed during the short duration of this trial; how-
ever, it is unclear if leptin’s known fat-reducing effects [61,62] 
were affected by the coadministration of pioglitazone. 
  Leptin’s effects on improving lipodystrophy have also been 
observed to act independently of the GH and insulin-like 
growth factor 1 (IGF-1) system [68]. As treatment with recom-
binant IGF-1/IGF-binding protein-3 [69] or GH and GH re-
leasing hormone (GHRH) analogs [70-72] have demonstrated 
decreases in visceral fat and improvement of lipodystrophy, a 
combination therapy with leptin could potentially have addi-
tive metabolic effects [68,73,74]. 
TREATMENT OF IMPAIRED GLUCOSE 
TOLERANCE IN LIPODYSTROPHY
A variety of treatment options have been studied to control 
the effects of HALS, but widely accepted guidelines have not 
yet been established. The target of ideal treatment for HALS 
would aim to treat both the metabolic disturbances and patho-
logical changes in adipose tissue distribution. Two of the most 
commonly used medications to treat the associated glucose 
intolerance include metformin and thiazolidinediones. Al-
though metformin is recommended for treatment of type 2 
diabetes mellitus it is not FDA-approved for lipodystrophy 
syndromes. Metformin treatment improves insulin sensitivity 
by decreasing hepatic gluconeogenesis and enhancing periph-
eral glucose utilization and thus has been shown in small, ran-
domized controlled trials to significantly reduce weight and 
insulin resistance in patients with HALS [75]. However, met-
formin is contraindicated in states that may predispose to lac-
tic acidosis, including states of impaired renal function, may 
worsen peripheral adipose tissue loss, and thus has been used 
with extreme caution in patients with lipoatrophy [65]. Thia-
zolidinediones are likewise not FDA-approved for use in lipo-
dystrophy. They bind and activate the PPAR-γ nuclear tran-
scription factor, which regulates adipocyte differentiation and 
promotes production of adiponectin [76]. We have shown that 
treatment with the only currently FDA approved TZD, piogli-
tazone, increases adiponectin and improves lipid profiles and 
insulin resistance over a 12-month period by decreasing tri-
glyceride levels and increasing HDL-C levels in patients with 
HALS [77]. 
CONCLUSIONS
Leptin administration, in replacement doses, has been shown 
in the context of long term, uncontrolled studies, to be effec-
tive in improving the metabolic and neuroendocrine abnor-
malities in subjects with congenital lipodystrophy. Thus, an 
application by Amylin Inc. has been submitted to the FDA for 
approval of leptin in replacement doses for the treatment of 
congenital lipodystrophy. It remains to be seen whether leptin 
will be approved for this indication in the absence of well con-
trolled, randomized studies that could allow a more precise 185
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assessment of efficacy and side effects. In the meantime, leptin 
is available through an expanded access program for subjects 
with congenital lipodystrophy and leptin deficiency. 
  As the global epidemic of HIV and associated comorbidities 
continues to have a striking impact, particularly in Southeast 
Asia, HALS is much more prevalent than congenital lipodys-
trophy and still represents a significant therapeutic challenge. 
Much more work is needed to better understand the patho-
genesis of HALS and to evaluate, in the context of large ran-
domized phase III clinical trials, novel therapy regimens such 
as adipokines, including leptin administration. Additional 
well-designed, placebo-controlled clinical trials of sufficient 
power and duration are needed to further evaluate mechanisms 
of action of leptin alone or in combination, dosing intervals 
and treatment duration for leptin treatments, as well as optimal 
drug combinations for treatment of lipodystrophy [46,49,50]. 
  In contrast to findings in leptin deficient lipodystrophic 
subjects, in subjects with garden-variety obesity or diabetes 
(who have high concentrations of not only insulin but also 
leptin presumably due to leptin tolerance or resistance) [78,79], 
treatment with additional exogenous leptin has not been asso-
ciated with significant weight loss or reduction in metabolic 
complications [20,80,81]. This suggests that there is leptin tol-
erance or resistance in these subjects [82,83]. Hence, although 
great progress has been made in understanding the role of 
leptin in many physiological systems, much research is current-
ly being directed toward elucidating the mechanisms and 
pathophysiology of leptin’s effects or resistance to leptin’s ef-
fects on glucose metabolism in subjects with excess adipose 
tissue and thus leptin excess.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES 
1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J 
Clin Endocrinol Metab 2004;89:2548-56.
2. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, 
Boone T, Collins F. Effects of the obese gene product on body 
weight regulation in ob/ob mice. Science 1995;269:540-3.
3. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza 
CG, Mantzoros CS. Leptin in human physiology and thera-
peutics. Front Neuroendocrinol 2010;31:377-93.
4. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation 
states: normal human physiology and clinical implications for 
hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005; 
366:74-85.
5. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabi-
nowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reduc-
ing effects of the plasma protein encoded by the obese gene. 
Science 1995;269:543-6.
6. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombi-
nant mouse OB protein: evidence for a peripheral signal link-
ing adiposity and central neural networks. Science 1995;269: 
546-9.
7. Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn 
BB, Mantzoros CS. Recombinant methionyl human leptin ad-
ministration activates signal transducer and activator of tran-
scription 3 signaling in peripheral blood mononuclear cells in 
vivo and regulates soluble tumor necrosis factor-alpha recep-
tor levels in humans with relative leptin deficiency. J Clin En-
docrinol Metab 2005;90:1625-31.
8. Houseknecht KL, Mantzoros CS, Kuliawat R, Hadro E, Flier 
JS, Kahn BB. Evidence for leptin binding to proteins in serum 
of rodents and humans: modulation with obesity. Diabetes 
1996;45:1638-43.
9. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, 
Mantzoros CS. Effects of acute and chronic administration of 
the melanocortin agonist MTII in mice with diet-induced 
obesity. Diabetes 2002;51:1337-45.
10. Bluher S, Mantzoros CS. Leptin in humans: lessons from trans-
lational research. Am J Clin Nutr 2009;89:991S-7S.
11. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in 
human physiology and pathophysiology: emerging clinical ap-
plications. Nat Clin Pract Endocrinol Metab 2006;2:318-27.
12. Brinkoetter M, Magkos F, Vamvini M, Mantzoros CS. Leptin 
treatment reduces body fat but does not affect lean body mass 
or the myostatin-follistatin-activin axis in lean hypoleptinemic 
women. Am J Physiol Endocrinol Metab 2011;301:E99-104.
13. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: 
the role of leptin in human physiology: emerging clinical ap-
plications. Ann Intern Med 2010;152:93-100.
14. Bluher S, Mantzoros CS. The role of leptin in regulating neuro-
endocrine function in humans. J Nutr 2004;134:2469S-74S.
15. Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, 
Mantzoros CS. Regulation of circulating soluble leptin recep-
tor levels by gender, adiposity, sex steroids, and leptin: obser-186
Mantzoros C S.
Diabetes Metab J 2012;36:181-189 http://e-dmj.org
vational and interventional studies in humans. Diabetes 2002; 
51:2105-12.
16. Chan JL, Mantzoros CS. Leptin and the hypothalamic-pituitary 
regulation of the gonadotropin-gonadal axis. Pituitary 2001;4: 
87-92.
17. Mantzoros CS. Role of leptin in reproduction. Ann N Y Acad 
Sci 2000;900:174-83.
18. Mantzoros CS. The role of leptin in human obesity and disease: 
a review of current evidence. Ann Intern Med 1999;130:671-80.
19. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: patho-
physiology and advances in treatment. Nat Rev Endocrinol 
2011;7:137-50.
20. Moon HS, Chamberland JP, Diakopoulos KN, Fiorenza CG, 
Ziemke F, Schneider B, Mantzoros CS. Leptin and amylin act 
in an additive manner to activate overlapping signaling path-
ways in peripheral tissues: in vitro and ex vivo studies in hu-
mans. Diabetes Care 2011;34:132-8.
21. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose 
tissue biology. Biochim Biophys Acta 2009;1791:507-13.
22. Chan JL, Oral EA. Clinical classification and treatment of con-
genital and acquired lipodystrophy. Endocr Pract 2010;16:310-
23.
23. Mantzoros CS. W(h)ither metreleptin for lipodystrophy and 
the metabolic syndrome? Endocr Pract 2010:1-18.
24. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adi-
ponectin and leptin levels in patients with lipodystrophies. J 
Clin Endocrinol Metab 2002;87:2395.
25. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, 
Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, 
Garg A. Leptin-replacement therapy for lipodystrophy. N Engl 
J Med 2002;346:570-8.
26. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, 
Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. 
Leptin reverses insulin resistance and hepatic steatosis in pa-
tients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.
27. Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replace-
ment therapy for lipoatrophic diabetes. N Engl J Med 2004; 
351:615-6.
28. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gor-
den P. Long-term efficacy of leptin replacement in patients with 
generalized lipodystrophy. Diabetes 2005;54:1994-2002.
29. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, 
Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonal-
coholic steatohepatitis in patients with severe lipodystrophy. 
Hepatology 2005;41:753-60.
30. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin 
therapy in the different forms of human lipodystrophy. Diabe-
tologia 2010;53:27-35.
31. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, 
Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, 
Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K. 
Efficacy and safety of leptin-replacement therapy and possible 
mechanisms of leptin actions in patients with generalized lipo-
dystrophy. J Clin Endocrinol Metab 2007;92:532-41.
32. Oral EA, Chan JL. Rationale for leptin-replacement therapy 
for severe lipodystrophy. Endocr Pract 2010;16:324-33.
33. Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, 
Gorden P. Clinical effects of long-term metreleptin treatment 
in patients with lipodystrophy. Endocr Pract 2011;17:922-32.
34. Savage DB, O’Rahilly S. Leptin therapy in lipodystrophy. Dia-
betologia 2010;53:7-9.
35. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, 
Oral EA, Turman MA, Blackett PR, Savage DB, O’Rahilly S, 
Balow JE, Gorden P. Proteinuric nephropathy in acquired and 
congenital generalized lipodystrophy: baseline characteristics 
and course during recombinant leptin therapy. J Clin Endocri-
nol Metab 2004;89:3199-207.
36. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006; 
78 Suppl 1:S7-12.
37. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of 
protease inhibitors on hyperglycemia, hyperlipidemia, and li-
podystrophy: a 5-year cohort study. Arch Intern Med 2000;160: 
2050-6.
38. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on 
Clinical Practices for Treatment of HIV. Guidelines for using 
antiretroviral agents among HIV-infected adults and adoles-
cents. Ann Intern Med 2002;137(5 Pt 2):381-433.
39. Dimock D, Thomas V, Cushing A, Purdy JB, Worrell C, Kopp 
JB, Hazra R, Hadigan C. Longitudinal assessment of metabolic 
abnormalities in adolescents and young adults with HIV-in-
fection acquired perinatally or in early childhood. Metabolism 
2011;60:874-80.
40. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnor-
malities in HIV-infected adults. N Engl J Med 2005;352:48-62.
41. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Hu-
man immunodeficiency virus/highly active antiretroviral ther-
apy-associated metabolic syndrome: clinical presentation, 
pathophysiology, and therapeutic strategies. J Clin Endocrinol 
Metab 2003;88:1961-76.
42. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C; Terry 187
Leptin in relation to the lipodystrophy-associated metabolic syndrome
Diabetes Metab J 2012;36:181-189 http://e-dmj.org
Beirn Community Programs for Clinical Research on AIDS 
(CPCRA); International Network for Strategic Initiatives in 
Global HIV Trials (INSIGHT). The effect of individual antiret-
roviral drugs on body composition in HIV-infected persons 
initiating highly active antiretroviral therapy. J Acquir Immune 
Defic Syndr 2009;51:298-304.
43. Estrada V, Serrano-Rios M, Martinez Larrad MT, Villar NG, 
Gonzalez Lopez A, Tellez MJ, Fernandez C. Leptin and adipose 
tissue maldistribution in HIV-infected male patients with pre-
dominant fat loss treated with antiretroviral therapy. J Acquir 
Immune Defic Syndr 2002;29:32-40.
44. Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, 
Hsu WC, Karchmer AW, Mantzoros CS. Human immunodefi-
ciency virus type 1-related lipoatrophy and lipohypertrophy 
are associated with serum concentrations of leptin. Clin Infect 
Dis 2003;36:795-802.
45. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Per-
ronne C, Basdevant A, Leport C, Chene G; Antiproteases Co-
horte (APROCO) Study Group. Factors related to lipodystro-
phy and metabolic alterations in patients with human immu-
nodeficiency virus infection receiving highly active antiretro-
viral therapy. Clin Infect Dis 2002;34:1396-405.
46. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Darde-
no TA, Kim SY, Hamnvik OP, Koniaris A. Leptin in human 
physiology and pathophysiology. Am J Physiol Endocrinol 
Metab 2011;301:E567-84.
47. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. In-
creased rates of lipolysis among human immunodeficiency vi-
rus-infected men receiving highly active antiretroviral therapy. 
Metabolism 2002;51:1143-7.
48. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: 
lipodystrophy associated with HIV-1 infection and antiretro-
viral treatment. Biochim Biophys Acta 2010;1801:392-9.
49. Tsiodras S, Mantzoros C. Leptin and adiponectin in the HIV 
associated metabolic syndrome: physiologic and therapeutic 
implications. Am J Infect Dis 2006;2:141-52.
50. Magkos F, Mantzoros CS. Body fat redistribution and metabol-
ic abnormalities in HIV-infected patients on highly active an-
tiretroviral therapy: novel insights into pathophysiology and 
emerging opportunities for treatment. Metabolism 2011;60: 
749-53.
51. van Vonderen MG, Blumer RM, Hassink EA, Sutinen J, Ack-
ermans MT, van Agtmael MA, Yki-Jarvinen H, Danner SA, 
Serlie MJ, Sauerwein HP, Reiss P. Insulin sensitivity in multiple 
pathways is differently affected during zidovudine/lamivudine-
containing compared with NRTI-sparing combination antiret-
roviral therapy. J Acquir Immune Defic Syndr 2010;53:186-93.
52. Roche R, Poizot-Martin I, Yazidi CM, Compe E, Gastaut JA, 
Torresani J, Planells R. Effects of antiretroviral drug combina-
tions on the differentiation of adipocytes. AIDS 2002;16:13-20.
53. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Pow-
derly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, 
Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group 
(ACTG) A5142 Study Team. Metabolic outcomes in a ran-
domized trial of nucleoside, nonnucleoside and protease in-
hibitor-sparing regimens for initial HIV treatment. AIDS 2009; 
23:1109-18.
54. Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, 
Heinklein P, Chrousos GP, Kopp JB. Human immunodeficien-
cy virus (HIV)-1 viral protein R suppresses transcriptional ac-
tivity of peroxisome proliferator-activated receptor {gamma} 
and inhibits adipocyte differentiation: implications for HIV-
associated lipodystrophy. Mol Endocrinol 2008;22:234-47.
55. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, 
Mantzoros CS. Hypoadiponectinemia is associated with insu-
lin resistance, hypertriglyceridemia, and fat redistribution in 
human immunodeficiency virus-infected patients treated with 
highly active antiretroviral therapy. J Clin Endocrinol Metab 
2003;88:627-36.
56. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipo-
kines in relation to HIV lipodystrophy. AIDS 2007;21:895-904.
57. Kadowaki T, Yamauchi T. Adiponectin and adiponectin recep-
tors. Endocr Rev 2005;26:439-51.
58. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki 
PJ, Grinspoon SK, Hotamisligil GS. Regulation of adiponectin 
in human immunodeficiency virus-infected patients: relation-
ship to body composition and metabolic indices. J Clin Endo-
crinol Metab 2003;88:1559-64.
59. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakha-
nian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum 
W, Capeau J, Bastard JP. Serum adipocytokines are related to 
lipodystrophy and metabolic disorders in HIV-infected men 
under antiretroviral therapy. AIDS 2003;17:1503-11.
60. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. 
Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J 
Biol Chem 2000;275:8456-60.
61. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Re-
combinant methionyl human leptin therapy in replacement 
doses improves insulin resistance and metabolic profile in pa-
tients with lipoatrophy and metabolic syndrome induced by the 188
Mantzoros C S.
Diabetes Metab J 2012;36:181-189 http://e-dmj.org
highly active antiretroviral therapy. J Clin Endocrinol Metab 
2006;91:2605-11.
62. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli 
AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M. 
The effects of recombinant human leptin on visceral fat, dys-
lipidemia, and insulin resistance in patients with human im-
munodeficiency virus-associated lipoatrophy and hypolepti-
nemia. J Clin Endocrinol Metab 2009;94:1137-44.
63. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon 
S. Metformin in the treatment of HIV lipodystrophy syndrome: 
a randomized controlled trial. JAMA 2000;284:472-7.
64. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon 
S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a 
randomized, controlled trial. Ann Intern Med 2004;140:786-94.
65. Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized place-
bo-controlled trial of metformin for the treatment of HIV li-
podystrophy. HIV Med 2007;8:420-6.
66. Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemp-
hill L, Lee H, Grinspoon S. Low-dose physiological growth hor-
mone in patients with HIV and abdominal fat accumulation: a 
randomized controlled trial. JAMA 2008;300:509-19.
67. Magkos F, Brennan A, Sweeney L, Kang ES, Doweiko J, Karch-
mer AW, Mantzoros CS. Leptin replacement improves post-
prandial glycemia and insulin sensitivity in human immuno-
deficiency virus-infected lipoatrophic men treated with piogli-
tazone: a pilot study. Metabolism 2011;60:1045-9.
68. Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimien-
ti SN, Wadhwa SG, Karchmer AW, Mantzoros CS. r-metHu-
Leptin improves highly active antiretroviral therapy-induced 
lipoatrophy and the metabolic syndrome, but not through al-
tering circulating IGF and IGF-binding protein levels: obser-
vational and interventional studies in humans. Eur J Endocri-
nol 2009;160:173-6.
69. Rao MN, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg 
M, Li X, Lang T, Grunfeld C, Schwarz JM, Schambelan M. Ef-
fects of insulin-like growth factor (IGF)-I/IGF-binding pro-
tein-3 treatment on glucose metabolism and fat distribution in 
human immunodeficiency virus-infected patients with abdom-
inal obesity and insulin resistance. J Clin Endocrinol Metab 
2010;95:4361-6.
70. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Re-
combinant human growth hormone improves the fat redistri-
bution syndrome (lipodystrophy) in patients with HIV. AIDS 
1999;13:2099-103.
71. Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, 
Muurahainen N, Kotler DP; Study 24380 Investigators Group. 
Recombinant human growth hormone to treat HIV-associated 
adipose redistribution syndrome: 12 week induction and 24-
week maintenance therapy. J Acquir Immune Defic Syndr 
2007;45:286-97.
72. Bickel M, Zangos S, Jacobi V, Lutz T, Knecht G, Goebel F, 
Staszewski S, Klauke S. A randomized, open-label study to 
compare the effects of two different doses of recombinant hu-
man growth hormone on fat reduction and fasting metabolic 
parameters in HIV-1-infected patients with lipodystrophy. 
HIV Med 2006;7:397-403.
73. Mantzoros CS. Whither recombinant human leptin treatment 
for HIV-associated lipoatrophy and the metabolic syndrome? 
J Clin Endocrinol Metab 2009;94:1089-91.
74. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Li-
olios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. 
Leptin concentrations in relation to body mass index and the 
tumor necrosis factor-alpha system in humans. J Clin Endo-
crinol Metab 1997;82:3408-13.
75. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metfor-
min therapy on markers of cardiovascular risk in human im-
munodeficiency virus-infected patients with fat redistribution 
and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-5.
76. Anghel SI, Bedu E, Vivier CD, Descombes P, Desvergne B, 
Wahli W. Adipose tissue integrity as a prerequisite for systemic 
energy balance: a critical role for peroxisome proliferator-acti-
vated receptor gamma. J Biol Chem 2007;282:29946-57.
77. Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, 
Moses AC, Karchmer AW, Mantzoros CS. Improvement in 
highly active antiretroviral therapy-induced metabolic syn-
drome by treatment with pioglitazone but not with fenofibrate: 
a 2×2 factorial, randomized, double-blinded, placebo-controlled 
trial. Clin Infect Dis 2005;40:745-9.
78. Mantzoros CS, Liolios AD, Tritos NA, Kaklamani VG, Doulger-
akis DE, Griveas I, Moses AC, Flier JS. Circulating insulin con-
centrations, smoking, and alcohol intake are important inde-
pendent predictors of leptin in young healthy men. Obes Res 
1998;6:179-86.
79. Mantzoros CS, Cramer DW, Liberman RF, Barbieri RL. Pre-
dictive value of serum and follicular fluid leptin concentra-
tions during assisted reproductive cycles in normal women 
and in women with the polycystic ovarian syndrome. Hum 
Reprod 2000;15:539-44.
80. Moon HS, Chamberland JP, Mantzoros CS. Amylin and leptin 
activate overlapping signalling pathways in an additive man-189
Leptin in relation to the lipodystrophy-associated metabolic syndrome
Diabetes Metab J 2012;36:181-189 http://e-dmj.org
ner in mouse GT1-7 hypothalamic, CC muscle and AML12 
liver cell lines. Diabetologia 2012;55:215-25.
81. Moon HS, Matarese G, Brennan AM, Chamberland JP, Liu X, 
Fiorenza CG, Mylvaganam GH, Abanni L, Carbone F, Wil-
liams CJ, De Paoli AM, Schneider BE, Mantzoros CS. Efficacy 
of metreleptin in obese patients with type 2 diabetes: cellular 
and molecular pathways underlying leptin tolerance. Diabetes 
2011;60:1647-56.
82. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner 
R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. 
Recombinant leptin for weight loss in obese and lean adults: a 
randomized, controlled, dose-escalation trial. JAMA 1999;282: 
1568-75.
83. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens 
TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, 
et al. Serum immunoreactive-leptin concentrations in normal-
weight and obese humans. N Engl J Med 1996;334:292-5.